NKTR - Company ID 0000906709
NEKTAR THERAPEUTICS (NKTR) reported net income of -$164.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$164.00M | -37.8% |
| FY 2024 | -$119.00M | +56.9% |
| FY 2023 | -$276.00M | +25.0% |
| FY 2022 | -$368.00M | +29.8% |
| FY 2021 | -$524.00M | -17.9% |
| FY 2020 | -$444.44M | -0.9% |
| FY 2019 | -$440.67M | -164.7% |
| FY 2018 | $681.31M | +804.6% |
| FY 2017 |
NEKTAR THERAPEUTICS (NKTR) reported net income of -$164.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, NEKTAR THERAPEUTICS's net income declined from -$133.98M to -$164.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$96.69M |
| +37.0% |
| FY 2016 | -$153.52M | -89.1% |
| FY 2015 | -$81.18M | -50.6% |
| FY 2014 | -$53.92M | +66.7% |
| FY 2013 | -$162.01M | +5.7% |
| FY 2012 | -$171.85M | -28.3% |
| FY 2011 | -$133.98M | - |